# Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer

> **NCT06841159** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 116 (estimated)

## Conditions studied

- Microsatellite Stable Metastatic Colorectal Cancer

## Interventions

- **RADIATION:** Ultra-fractionated radiation therapy
- **DRUG:** Sintilimab
- **DRUG:** Standard systemic therapy

## Key facts

- **NCT ID:** NCT06841159
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-01
- **Primary completion:** 2026-03-01
- **Final completion:** 2028-03-01
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06841159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06841159, "Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06841159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*